These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15963014)

  • 1. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.
    Garrison LP; Zamora B; Li M; Towse A
    J Manag Care Spec Pharm; 2020 Apr; 26(4):400-406. PubMed ID: 32223599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health resource allocation. A made-in-Canada description.
    Noseworthy T
    J Leg Med; 2011 Jan; 32(1):11-26. PubMed ID: 21391053
    [No Abstract]   [Full Text] [Related]  

  • 6. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
    Robertson J; Walkom EJ; Bevan MD; Newby DA
    BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
    Wonder MJ; Neville AM; Parsons R
    Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
    Moon S; Erickson E
    N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
    [No Abstract]   [Full Text] [Related]  

  • 11. Maintaining the vaccine safety net.
    Hannan C; Buchanan AD; Monroe J
    Pediatrics; 2009 Dec; 124 Suppl 5():S571-2. PubMed ID: 19948593
    [No Abstract]   [Full Text] [Related]  

  • 12. The Right to Health: Implications for the Funding of Medicines in Australia.
    Harper C; Ghinea N; Lipworth W
    J Law Med; 2017; 24(3):640-55. PubMed ID: 30137760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 14. National pharmacare: a dog's tale.
    Anis AH
    CMAJ; 2004 Sep; 171(6):565-6. PubMed ID: 15367455
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient assistance programs: information is not our enemy.
    Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH
    Health Aff (Millwood); 2009; 28(3):843-4. PubMed ID: 19414896
    [No Abstract]   [Full Text] [Related]  

  • 16. The Australian Managed Entry Scheme: Are We Getting it Right?
    Tuffaha HW; Scuffham PA
    Pharmacoeconomics; 2018 May; 36(5):555-565. PubMed ID: 29478116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hard decisions about fundamental values.
    Laupacis A
    Healthc Pap; 2004; 4(3):60-6; discussion 68-72. PubMed ID: 15114071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
    Doran E; Robertson J
    Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.